Healthcare Real Estate and Healthcare Venture Capital

Most investors treat healthcare real estate and healthcare venture capital as two unrelated things. One is an income asset underwritten on lease terms, tenant credit, and cap rates. The other is a growth asset underwritten on addressable markets, clinical evidence, and burn rate. They sit in different pockets of a portfolio and usually get evaluated by different people.

The data coming out of the first half of 2026 argues that the separation is a mistake. The same demographic and regulatory forces drive both, and increasingly they drive them into the same physical buildings. What follows makes the detailed case for healthcare real estate first, because that is where the evidence is most measurable, and then turns to where venture capital enters the picture and why the two theses are structurally linked.

The Demand Curve Is Already Written Down

Almost every real estate thesis depends on a forecast about human behavior. Retail depends on how people shop. Office depends on how firms organize work. Multifamily depends on household formation and wage growth. Each of those can reverse, and each has.

Healthcare real estate rests on something narrower and considerably harder to argue with. According to the U.S. Census Bureau, 2030 marks a demographic turning point: beginning that year every baby boomer will be older than 65, which expands the older population so that roughly one in every five Americans is projected to be retirement age. By 2034 the Census Bureau projects that older adults will outnumber children for the first time in the nation’s history. S&P Global Market Intelligence, drawing on Claritas projections, put the 65-and-over cohort at 62.7 million in 2025 and 71.6 million by 2030, about 20.7% of the population.

The people who will generate that demand are alive today. They are not a projection about preferences or sentiment. They are a headcount. Older adults consume outpatient services at multiples of the rate of working-age adults, and the 80-plus segment, which consumes most intensively of all, grows fastest in the decade following. This is the floor beneath everything else in this article.

What the Buildings Are Actually Doing

Demographic arguments are easy to make and easy to overstate, so it is worth examining what medical outpatient buildings are producing right now rather than what they are supposed to produce eventually.

Cushman & Wakefield’s 2026 Vital Signs report found that medical outpatient building absorption reached 3.8 million square feet in the first quarter of 2026 alone, up 71% year over year, pushing occupancy to 92.5% across the top 50 U.S. markets. Investment sales totaled $1.8 billion in that quarter, a 36% year-over-year increase, with rolling four-quarter volume reaching $9.8 billion, up 49%. Cap rates have stabilized near 6.7%.

JLL’s 2026 Medical Outpatient Building Perspective reported record occupancy of 92.7% and noted that average rent growth continues to outpace the broader office market. JLL also made an observation that deserves more attention than it usually receives: of the top ten growth areas for patient volumes, eight are in outpatient services.

CBRE’s 2026 outlook is more conservative on vacancy, projecting that MOB vacancy will stabilize within its ten-year range of 9.5% to 10.5% while average MOB rent climbs to a record high, with rent growth accelerating to 1.4% in 2026 from 0.9% in 2025. The apparent gap between CBRE’s vacancy figures and the occupancy readings from Cushman & Wakefield and JLL is largely a question of which universe of buildings each firm measures. That is a useful reminder to check the sample before comparing headline numbers across brokerages, and a reason to be skeptical of any single figure quoted without its source.

Directionally, all three agree. Occupancy sits at or near record levels, rents are rising, and transaction capital is returning to the sector.

Supply Is the Part Most Investors Miss

The strongest argument for medical outpatient buildings in 2026 is not demand. Demand is well understood and substantially priced in. The argument is supply.

JLL reported that MOB construction starts fell in 2023, bottomed in the fourth quarter of 2024 at roughly 1% of existing inventory, and recovered only slightly during the second half of 2025 to about 1.1%. Speculative development remains limited. Health systems lead most construction starts and then occupy a large share of what they build, which leaves very little new supply available to third-party tenants.

The cumulative effect is visible in the aggregate. Work published by PwC and ULI noted that across a recent three-year window, 44.4 million square feet of MOB space was completed within the top 100 metro areas while absorption increased by 48.9 million square feet. Absorption outran delivery by roughly 4.5 million square feet over three years.

When absorption consistently outpaces deliveries, landlords gain pricing power. JLL observed exactly that, adding that lease structures are trending toward more aggressive escalations. For an owner, escalation language is frequently worth more across a full hold period than the initial cap rate, and it is also the first term conceded in softer markets. Getting it in writing during a constrained market is one of the more durable advantages available in this asset class right now.

The Policy Engine Behind the Migration

Demographics explain why healthcare demand grows. Policy explains why that demand is moving into outpatient buildings specifically.

On November 21, 2025, the Centers for Medicare and Medicaid Services issued the calendar year 2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center final rule, effective January 1, 2026. CMS finalized a 2.6% update to ASC payment rates and continued aligning ASC inflation updates with the inpatient market basket rather than the consumer price index. More consequentially, the agency moved to phase out the Medicare Inpatient-Only List and expanded the ASC Covered Procedures List.

That combination matters far more than the headline payment percentage. Every procedure removed from the inpatient-only list becomes a procedure that can legally and economically be performed outside a hospital. Analysis from Holland & Knight noted that the payment update combined with significant expansions to the covered procedures list may shift meaningful service volume from hospital outpatient departments into lower-cost ASC settings over time. Cardiovascular, spine, and advanced orthopedic cases are widely expected to lead that migration.

Every one of those procedures needs a room, and those rooms need specific things: higher floor loads for imaging equipment, upgraded HVAC and medical gas, generous parking ratios, ground-floor access, and proximity to the patient population. Those requirements are precisely why medical outpatient space does not convert easily from conventional office inventory, and why the supply constraint is more durable than a simple construction-pipeline chart suggests.

Why Medical Net Lease Behaves Differently

Healthcare tenants are unusually sticky. A dermatology group or an ambulatory surgery center that has sunk seven figures into build-out, imaging equipment, and address-specific licensure does not relocate to save a dollar per square foot. Patient routing, referral patterns, and state licensing all attach to the physical location. Renewal probability in medical outpatient space runs well above conventional office for this reason, and that advantage flows directly into underwriting through lower assumed downtime, reduced releasing costs, and smaller tenant improvement reserves.

The credit question still deserves the same discipline you would bring to any net lease acquisition. Tenant quality across healthcare spans investment grade health systems at one end and single-physician practices with no rating at all at the other, and the spread between those two is wider than most buyers assume. The same principles that govern any triple net purchase apply here, and our guide to investment grade NNN tenants covers how to verify a tenant’s credit tier before writing a letter of intent.

Institutional capital has clearly reached its own conclusion. In the fourth quarter of 2025, Welltower disposed of a $7.2 billion portfolio to Remedy Medical Properties and Kayne Anderson, according to JLL. Transactions at that scale do not clear without genuine conviction about the durability of the underlying cash flow.

Where Healthcare Venture Capital Enters

Everything above concerns the container. The more interesting question is what is happening inside it.

The same outpatient migration that fills medical office buildings simultaneously creates the operating companies that occupy them. An ambulatory surgery platform, a specialty clinic network, an imaging operator, or a longevity practice is a tenant and an operating business at the same time. The venture side of healthcare is currently showing much the same durability as the real estate. According to Rock Health, U.S. digital health companies raised $7.4 billion across 244 deals in the first half of 2026, up from $6.4 billion across roughly the same number of financings a year earlier, with median deal size rising to $14 million from $12 million. Rounds of $100 million or more accounted for 45% of all capital invested, and the sector recorded 115 acquisitions in the first half alone. Mental health was the top-funded clinical indication for the seventh consecutive year, with weight management second on the strength of GLP-1 demand. Investors who want exposure to the operating layer rather than the building can access it through vehicles such as a dedicated healthcare venture capital fund, which structures physician-side co-investment into companies driving the same outpatient shift that supports the underlying real estate.

Buildings and Businesses Are the Same Trade

The insight connecting the two sides is simple to state and easy to miss. Healthcare is not one industry. It is two. One side is infrastructure: the physical clinics, surgery centers, and specialty offices where care is delivered. The other is the operating layer: the companies, technologies, and platforms that determine how that care is delivered, paid for, and measured. Most investors pick one side and stay there. The demographic and regulatory forces described in this article do not respect that boundary.

Consider what CMS actually did in the 2026 rule. Expanding the ASC covered procedures list increases the number of surgical cases that can be performed outside a hospital. That single change raises demand for outpatient facilities, which is a real estate outcome, and simultaneously improves the unit economics of ambulatory surgery operators, which is a venture and growth equity outcome. One regulatory action, two asset classes, same direction.

The practical advantage runs in both directions. An investor who underwrites medical outpatient buildings develops a granular feel for which specialties are expanding, which operators sign leases and then actually pay them, and which service lines are gaining volume in a given metro. That is operating intelligence most venture investors never acquire, because they evaluate companies through pitch decks rather than through rent rolls. Conversely, an investor tracking where venture capital is funding new care models gains an early read on which tenants will be signing leases three years from now. Rent rolls are a lagging indicator of the same shift that funding rounds lead.

The Honest Counterweight

A case this favorable deserves its counterarguments stated plainly rather than buried.

Reimbursement is the central risk. The same rulemaking process that expands the covered procedures list can compress payment rates in a later cycle, and a practice whose economics depend on a specific reimbursement schedule is only as creditworthy as that schedule. JLL flagged directly that policy changes and financial pressures are heightening risk for both occupiers and investors, with uncompensated care burdens rising as hospital system margins tighten.

Elevated construction costs cut both ways. They constrain new supply, which benefits existing owners, but they also raise the basis on any new development and make ground-up projects harder to pencil. Cap rates near 6.7% are described as stabilized rather than compressing, so no one should underwrite meaningful cap rate compression as a source of return in this cycle. Tenant credit dispersion is genuinely wide, and a medical building with a weak private practice tenant is not a defensive asset simply because the sign on the door says healthcare.

On the venture side, capital concentration cuts both ways as well. When 45% of all dollars flow into rounds of $100 million or more, the median company is not experiencing the funding environment the headline number implies. Early-stage healthcare venture remains illiquid, typically across a seven to ten year horizon, and it carries a materially different risk profile from a leased building with a contractual rent stream. These are complementary exposures, not substitutes, and they should be sized accordingly.

How to Underwrite It

For investors evaluating medical outpatient assets in this market, a few questions matter more than the rest. What is the tenant’s actual credit tier, verified rather than assumed? How much of the practice’s revenue depends on a reimbursement code that CMS could revisit? What are the annual escalations, and do they compound? How much address-specific capital has the tenant sunk into build-out and licensure, since that number is the single best predictor of renewal? And what is the realistic conversion cost if that tenant does leave, given that medical space rarely re-lets to conventional office users?

The demographic case for healthcare real estate is as close to certain as anything in commercial property. The execution case still depends entirely on tenant selection, lease structure, and basis. Those have always been the variables that separate a durable income asset from a building that happens to have a doctor in it.